NWBO's market cap of $300 million is too low. Here is why?
A billion dollar drug on approval gets a $400 million market cap during phase III. This only takes into account "L" and the fact they have Direct should only add to the $400 million.
The Street editor has also put out a response early this morning. To address the timing of the 18 hit pieces she only draws attention to one that came 2 weeks after a positive PR by NWBO. She has selective memory. Afraid they may face civil charges. This is heating up.
It is the timing of everyone of AF's posts. The inflammatory nature and half truths put up as assertions like "MD Anderson Rebukes NWBO", when no such thing happened. One doctor not associated with the testing didn't like a practice NW did that he has done himself in the past. It is the naked short selling that is illegal and the dark pool trading that occurs between short sellers driving the price down.
If that isn't enough to form an investigation then the justice system shouldn't exist. The LA times reporter didn't mention anything I just put up. He is missing the point and sweeping it under the rug.
IHub is having a conversation about it. No its Not! Yes they do! I don't think so!. The only thing to end this is an investigation by the DA. The SEC is useless. Lets see if the DA steps in.
Minimal work. Really? They developed the manufacturing process that will be used. They are the ones that got it from 3 months to 8 days. The office of NWBO does not do the testing, vaccine development or manufacturing. They have a few technical people that coordinate the work. Unlike you I think Cognate deserves payment.
You got Direct data when she didn't have to, only to get slammed by the shorts. You still need to wait for "L" data but the fact that Germany will start paying for the product and the UK will decide on the product by the end of the year tells you more than you would ever get from a biotech. Also the worst 55 patients that got "L" but were so bad they were not included in the trials have done better than typical standard of care.
You never get an early look like this on a drug trial. Take it as a gift.
Frustrating that he can insinuate a lower conversion price than $5.84 and people believe it. Like you stated, "unbelievable nonsense". They will need more funds but with decent news on Direct the share price will exceed the old options and some warrants. There will be no need for another raise. Amazing what these folks can do to a retail investor. Still waiting for some analyst. Someone mentioned the accuracy of the Yahoo analyst section. It doesn't include all analysts. Zack's Zeng was around $12 and he is never listed.
But in Germany and the UK......They can make a profit.
Well, anyone who can read the document knows the conversion can't be renegotiated below $5.84. Why should they reply. He came up with an idiot argument.
The best part is his guess that the converts will go for lower than $5.84. How wrong is that. The folks already ponied up the funds. Lowering the price of conversion won't happen because the debtor has zero leverage unless the company doesn't find financing again and goes bankrupt. Hard to believe. They sold shares at $7.50 before the $6.50 offering.